US Trial Finds AstraZeneca 79 Percent Effective, No Blood Clot Risk

Several countries had advised against administering the jab to older people due to a lack of data among elderly participants in previous trials
Earlier this month several countries also paused use of the vaccine over fears it poses blood clot risks

AstraZeneca’s Covid-19 vaccine is 80 percent effective at preventing the disease in the elderly and does not increase the risk of blood clots, the biotech firm said Monday, following its US phase III efficiency trials.

It was 79 percent effective at preventing symptomatic Covid-19 in the overall population and 100 percent effective at preventing severe disease and hospitalization, it said.

According to a statement by the pharmaceutical firm said in a statement, the US phase III trial of the vaccine developed by AstraZeneca and Oxford University involved 32,449 participants, with two thirds receiving the jab.

Around 20 percent were 65 or older, and about 60 percent had health conditions associated with a higher risk of severe Covid-19, such as diabetes, severe obesity or cardiac disease.

“These findings reconfirm previous results observed in AZD1222 trials across all adult populations but it’s exciting to see similar efficacy results in people over 65 for the first time,” said Ann Falsey, professor of medicine at University of Rochester School of Medicine and co-lead principal investigator for the trial.

“This analysis validates the AstraZeneca Covid-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”

The trial’s independent data safety monitoring board found no increased risk of thrombosis among the 21,583 participants who received at least one dose, the statement said.

YOU MAY ALSO LIKE